USFDA classifies Lupin's Pithampur Unit-2 inspection as OAI

06 Oct 2025 Evaluate

United States Food and Drug Administration (USFDA) has classified Lupin's Pithampur Unit-2 manufacturing facility inspection as Official Action Indicated (OAI). The Company is working with the USFDA to satisfactorily resolve the compliance issues and is committed to be compliant with CGMP standards at all its manufacturing facilities.

The inspection was undertaken by USFDA at Lupin’s Pithampur Unit-2 manufacturing facility from July 8 to July 17, 2025, wherein the inspection was closed with the issuance of a Form-483 with four observations.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

1971.50 15.45 (0.79%)
07-Nov-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1692.75
Dr. Reddys Lab 1205.30
Cipla 1504.45
Zydus Lifesciences 943.80
Lupin 1971.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×